FAPA

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, June 29, 2023

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Shareholders will be entitled to receive US$1.12 in cash for each share held immediately prior to the effective time of the take-private transaction.
  • The transaction is currently contemplated to close in the third calendar quarter of 2023, subject to satisfaction of certain closing conditions.
  • On April 3, 2023, Reunion announced that it appointed seasoned pharmaceutical executive, Fred Grossman, D.O., FAPA, to its Board of Directors.
  • Drug Effect Questionnaire and Mystical Effect Questionnaire scores observed at these dose levels indicate the potential for therapeutic effect.

Pilot Staffing Crisis Sees Solutions Starting on the “Ninth Island”* in Las Vegas before Hitting the Beaches at Honolulu Recruitment Event

Retrieved on: 
Thursday, May 11, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230511005901/en/
    Leading pilot talent scout Todd Wesoloskie and representatives from SkyWest Charter will be among the featured speakers at the event.
  • Attendees will meet with pilot recruiters from Wheels Up, SkyWest Charter and Ameristar with opportunities to arrange on-site interviews.
  • FAPA Pilot Job Fairs are free for job-hunting pilots to attend; however, a current pilot résumé is required for admission.
  • The monthly event brings flight school representatives together to meet with prospective students seeking a new professional pilot career.

United Bankshares, Inc. Holds Annual Meeting of Shareholders

Retrieved on: 
Wednesday, May 10, 2023

United Bankshares, Inc. (“United”) (NASDAQ: UBSI ), a $30 billion regional financial services company held its Annual Meeting of Shareholders on Wednesday, May 10, 2023, at Congressional Country Club in Bethesda, Maryland.

Key Points: 
  • United Bankshares, Inc. (“United”) (NASDAQ: UBSI ), a $30 billion regional financial services company held its Annual Meeting of Shareholders on Wednesday, May 10, 2023, at Congressional Country Club in Bethesda, Maryland.
  • During the meeting, United Executive Chairman of the Board Richard M. Adams addressed the shareholders by highlighting several key points from the 2022 Annual Report to Shareholders.
  • “In 2022 we achieved record earnings and increased dividends to our shareholders for the 49th consecutive year.
  • This is a record only one other major banking company in the nation has been able to achieve,” stated Adams.

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Retrieved on: 
Monday, April 3, 2023

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, pharmacovigilance and health outcomes across a variety of products, including biologics and small molecules.

Key Points: 
  • Dr. Grossman has over two decades of experience in clinical development and medical affairs, pharmacovigilance and health outcomes across a variety of products, including biologics and small molecules.
  • “Reunion is developing proprietary novel drug candidates designed to target specific serotonergic receptors in the brain for the potential treatment of serious mental health conditions,” added Dr. Grossman.
  • He has authored numerous scientific publications and has held academic appointments at several universities.
  • He completed his residency in psychiatry at Hahnemann University and a pharmacology fellowship at the National Institutes of Health (NIH).

REVERIE MIND LAUNCHES "URGENT" PROGRAM TO PROVIDE SUBOXONE THERAPY TO ADULTS AND ADOLESCENTS IN NEED

Retrieved on: 
Thursday, March 30, 2023

Our URGENT program is designed to provide care to patients who are in need of Suboxone Therapy for opioid use disorder.

Key Points: 
  • Our URGENT program is designed to provide care to patients who are in need of Suboxone Therapy for opioid use disorder.
  • "The launch and formation of the URGENT program is designed to provide immediate aid to patients who are in need of addiction therapy.
  • Our URGENT program is led by our Medical Director, Dr. Lauro Amezcua-Patino MD, FAPA which had the following to say, "Reverie Mind is the premiere provider of psychedelic research, ketamine, and suboxone therapy in Arizona.
  • To learn more about Reverie Mind and our URGENT program, please call us at 1-855-738-6463 or visit us at www.reveriemind.com

Discovery Behavioral Health Wraps 2022 With Acquisitions of Leading Treatment Centers and Expansion into Major Markets, Executive Appointments, and Launch of DiscoveryMD

Retrieved on: 
Wednesday, January 4, 2023

As well, the company announced several C-suite appointments and the launch of a new division, DiscoveryMD.

Key Points: 
  • As well, the company announced several C-suite appointments and the launch of a new division, DiscoveryMD.
  • In February, DBH began the year by acquiring Dan Med TMS Neuro Institute, a leading treatment center specializing in TMS therapy for depression.
  • "In 2022 we continued to build upon the foundation of our unprecedented expansion of traditional and virtual care in 2021.
  • That's why Discovery Behavioral Health has made evidence-based, outcome driven healthcare accessible and affordable since inception.

FAPA To Host Future Pilot Seminar for Aspiring Aviators

Retrieved on: 
Thursday, November 17, 2022

Our Future Pilot Seminar is free for everyone to attend, and were here to help, said Tim Genc, chief advisor and executive editor of FAPA.

Key Points: 
  • Our Future Pilot Seminar is free for everyone to attend, and were here to help, said Tim Genc, chief advisor and executive editor of FAPA.
  • That guidance and direction can be found at the Future Pilot Seminar hosted by the FAPA organization.
  • The FAPA seminar is a one-stop shop for providing a future pilot with all the data that is needed to make an informed decision about becoming a pilot.
  • In my opinion, the FAPA Future Pilot seminar is an absolute must for any aspiring pilot, said Glenn Thompkins, vice president, educational partnerships, Spartan College of Aeronautics and Technology.

FAPA and JetBlue Partner for Exclusive Recruiting Event in South Florida as Airline Pilot Hiring Reaches Record Levels in the US

Retrieved on: 
Wednesday, November 16, 2022

The latest aviation data shows pilot hiring numbers are soaring to never-before-seen levels in the industry, with 2022 surpassing the record for pilot hiring, previously achieved in 2000.

Key Points: 
  • The latest aviation data shows pilot hiring numbers are soaring to never-before-seen levels in the industry, with 2022 surpassing the record for pilot hiring, previously achieved in 2000.
  • Talent acquisition professionals in our industry understand the value and effectiveness of recruiting events based on merits and accomplishments.
  • JetBlue is proud and excited to continue our partnership with FAPA as we seek dedicated and professional pilots to join our growing airline.
  • In addition, the team has experience in airline, corporate, cargo, and military aviation, as well as commercial publishing.

FAPA and Wheels Up to Host Pilot Hiring Event in Atlanta

Retrieved on: 
Tuesday, November 15, 2022

Pilot career consulting company Future & Active Pilot Advisors (FAPA) is partnering with one of the largest private aviation companies in the world, Wheels Up, to host the Wheels Up Pilot Hiring Event on Wednesday, November 16, 2022, from 8 am-5 pm at the Atlanta Airport Marriott (4711 Best Road Atlanta, GA, 30337).

Key Points: 
  • Pilot career consulting company Future & Active Pilot Advisors (FAPA) is partnering with one of the largest private aviation companies in the world, Wheels Up, to host the Wheels Up Pilot Hiring Event on Wednesday, November 16, 2022, from 8 am-5 pm at the Atlanta Airport Marriott (4711 Best Road Atlanta, GA, 30337).
  • The Wheels Up Pilot Hiring Event follows the New York-City based companys recent announcement of their new Member Operations Center (MOC) to open next year in Chamblee, GA and its recent partnership with Delta Air Lines Propel Pilot Career Path Program.
  • Wheels Up, the only private aviation company on the NYSE, will hold an exclusive pilot recruiting and hiring event near the Atlanta Airport this Wednesday, November 16.
  • Individuals with pilot-in-command experience in various aircraft are invited to register for this free event, says Tim Genc, chief advisor and executive editor of FAPA.

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

Retrieved on: 
Tuesday, October 18, 2022

Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS).

Key Points: 
  • Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS).
  • Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms.
  • As part of its genetic engineering platform, the company has licensed CRISPR/Cas9 technology from ERS Genomics for genetic engineering applications related to its therapeutic pipeline.
  • Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders.